• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. Dec 1990; 137(6): 1299–1304.
PMCID: PMC1877729

Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.

Abstract

Vimentin expression in tumors from 83 node-negative and 112 node-positive patients with infiltrative ductal not otherwise specified (NOS) breast carcinomas has been compared with 5-year survival. For node-negative, but not for node-positive patients, there was a significant inverse relation between vimentin expression and survival. Five-year survival of node-negative patients with vimentin-positive tumors was significantly worse compared with vimentin-negative tumors (P less than 0.0001). In the node-negative group, only 36% of patients with vimentin-positive tumors but 82% of patients with vimentin-negative tumors survived 5 years. Tumors of all eight node-negative patients with ductal NOS cancer who died in the first 27 months expressed vimentin. Multivariate analysis of the node-negative group showed a strong correlation of vimentin expression and overall survival, but weak and not significant correlation between histologic grade or size and overall survival at 5 years. Thus vimentin expression seems to be a strong indicator of poor prognosis in node-negative ductal NOS breast carcinomas.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (805K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol. 1990 Jan;136(1):219–227. [PMC free article] [PubMed]
  • Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer. 1988 Apr;57(4):353–357. [PMC free article] [PubMed]
  • Raymond WA, Leong AS. Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol. 1989 Apr;157(4):299–306. [PubMed]
  • Raymond WA, Leong AS. Vimentin--a new prognostic parameter in breast carcinoma? J Pathol. 1989 Jun;158(2):107–114. [PubMed]
  • Charpin C, Andrac L, Vacheret H, Habib MC, Devictor B, Lavaut MN, Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed]
  • Meyer JS, Lee JY. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 1980 Jun;40(6):1890–1896. [PubMed]
  • Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. [PubMed]
  • Silvestrini R, Daidone MG, Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer. 1985 Oct 15;56(8):1982–1987. [PubMed]
  • Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 1987 Nov 15;47(22):6126–6133. [PubMed]
  • Viac J, Reano A, Brochier J, Staquet MJ, Thivolet J. Reactivity pattern of a monoclonal antikeratin antibody (KL1). J Invest Dermatol. 1983 Oct;81(4):351–354. [PubMed]
  • Osborn M, Debus E, Weber K. Monoclonal antibodies specific for vimentin. Eur J Cell Biol. 1984 May;34(1):137–143. [PubMed]
  • BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. [PMC free article] [PubMed]
  • Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol. 1988 Nov;19(11):1340–1346. [PubMed]
  • Bloom HJ, Richardson WW, Field JR. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J. 1970 Jul 25;3(5716):181–188. [PMC free article] [PubMed]
  • Gerdes J, Pickartz H, Brotherton J, Hammerstein J, Weitzel H, Stein H. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol. 1987 Dec;129(3):486–492. [PMC free article] [PubMed]
  • McGurrin JF, Doria MI, Jr, Dawson PJ, Karrison T, Stein HO, Franklin WA. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15;59(10):1744–1750. [PubMed]
  • Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988 Sep 1;62(5):989–993. [PubMed]
  • Osborne CK, Yochmowitz MG, Knight WA, 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. [PubMed]
  • Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed]
  • Bacus SS, Goldschmidt R, Chin D, Moran G, Weinberg D, Bacus JW. Biological grading of breast cancer using antibodies to proliferating cells and other markers. Am J Pathol. 1989 Nov;135(5):783–792. [PMC free article] [PubMed]
  • Donhuijsen K, Schulz S. Prognostic significance of vimentin positivity in formalin-fixed renal cell carcinomas. Pathol Res Pract. 1989 Mar;184(3):287–291. [PubMed]
  • Medeiros LJ, Michie SA, Johnson DE, Warnke RA, Weiss LM. An immunoperoxidase study of renal cell carcinomas: correlation with nuclear grade, cell type, and histologic pattern. Hum Pathol. 1988 Aug;19(8):980–987. [PubMed]
  • Domagala W, Lasota J, Chosia M, Szadowska A, Weber K, Osborn M. Diagnosis of major tumor categories in fine-needle aspirates is more accurate when light microscopy is combined with intermediate filament typing. A study of 403 cases. Cancer. 1989 Feb 1;63(3):504–517. [PubMed]
  • Marchetti E, Bagni A, Querzoli P, Durante E, Marzola A, Fabris G, Nenci I. Immunocytochemical detection of estrogen receptors by staining with monoclonal antibodies on cytologic specimens of human breast cancer. Acta Cytol. 1988 Nov-Dec;32(6):829–834. [PubMed]
  • McGuire WL. Adjuvant therapy of node-negative breast cancer. N Engl J Med. 1989 Feb 23;320(8):525–527. [PubMed]
  • O'Reilly SM, Richards MA. Node negative breast cancer. BMJ. 1990 Feb 10;300(6721):346–348. [PMC free article] [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...